Emkay Global Financial is bullish on Indian Oil has recommended buy rating on the stock with a target price of Rs 85 in its research report dated October 30, 2022.
Posts tagged MC
Buy Bandhan Bank; target of Rs 330: Emkay Global Financial (31-10-2022)
Emkay Global Financial is bullish on Bandhan Bank has recommended buy rating on the stock with a target price of Rs 330 in its research report dated October 29, 2022.
Buy Bandhan Bank; target of Rs 330: Emkay Global Financial (31-10-2022)
Emkay Global Financial is bullish on Bandhan Bank has recommended buy rating on the stock with a target price of Rs 330 in its research report dated October 29, 2022.
Reduce Indian Oil Corporation; target of Rs 50: Prabhudas Lilladher (31-10-2022)
Prabhudas Lilladher recommended Reduce rating on Indian Oil Corporation with a target price of Rs 50 in its research report dated October 31, 2022.
Reduce Indian Oil Corporation; target of Rs 50: Prabhudas Lilladher (31-10-2022)
Prabhudas Lilladher recommended Reduce rating on Indian Oil Corporation with a target price of Rs 50 in its research report dated October 31, 2022.
Buy Dr. Reddy#39;s Laboratories; target of Rs 4900: Prabhudas Lilladher (31-10-2022)
Prabhudas Lilladher is bullish on Dr. Reddy#39;s Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated October 31, 2022.
Buy Dr. Reddy#39;s Laboratories; target of Rs 4900: Prabhudas Lilladher (31-10-2022)
Prabhudas Lilladher is bullish on Dr. Reddy#39;s Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated October 31, 2022.
Buy Maruti Suzuki; target of Rs 10,230: Prabhudas Lilladher (31-10-2022)
Prabhudas Lilladher is bullish on Maruti Suzuki has recommended buy rating on the stock with a target price of Rs 10,230 in its research report dated October 31, 2022.
Buy Maruti Suzuki; target of Rs 10,230: Prabhudas Lilladher (31-10-2022)
Prabhudas Lilladher is bullish on Maruti Suzuki has recommended buy rating on the stock with a target price of Rs 10,230 in its research report dated October 31, 2022.
What does g-Revlimid launch mean for Dr Reddy’s margin trajectory? (31-10-2022)
Emerging markets, including India, would remain the chief driver of top-line growth